, and
From the editorial: “Those who manage and fund Canada’s health care systems need to view high-priority trials as an integral part of clinical care and to provide adequate and stable infrastructure funding, thus avoiding the current time-consuming and expensive process of developing separate data-sharing agreements and contracts with many hospitals and organizations. ”
Can J Kidney Health Dis., 26 Aug 2020
Bhanu Prasad (Communications and Engagement committee member), Maryam Jafari, Kaval Kour, Kunal Goyal, Francisco Garcia
J Pain Symptom Manage., 14Aug2020
David Collister (Scientific Operations and Executive committee member), Karthik Tennankore (Scientific Operations and Executive committee member), Sara N. Davison, Ron Wald, Christian Rabbat, Michael Walsh
Can J Kidney Health Dis., 10Aug2020
Lucas Diebel, Maryam Jafari, Sachin Shah, Christine Day, Connie McNaught, Bhanu Prasad (Communications and Engagement committee member)
BMC Health Serv Res., 10 Aug 2020
Can J Kidney Health Dis., 04 Aug 2020
Rachel M. Holden, Reem A. Mustafa, R. Todd Alexander, Marisa Battistella, Micheli U. Bevilacqua, Greg Knoll, Fabrice Mac-Way, Martina Resilerova, Ron Wald, Philip D. Acott, Patrick Feltmate, Allan Grill, Kailash K. Jindal, Meena Karsanji, Bryce A. Kiberd, Sara Mahdavi, Kallee McCarron, Amber O. Molnar (CNTN Communications and Engagement Committee co-chair), Maury Pinsk, Celia Rodd, Steven D. Soroka, Amanda J. Vinson, Deborah Zimmerman, Catherine M. Clase (CNTN Scientific Operations Committee member)
N Engl J Med, 16 Jul 2020
Can J Kidney Health Dis., 04 Jun 2020
Bhanu Prasad (Communications and Engagement Committee member), Maryam Jafari, Julie Toppings, Linda Gross, Joanne Kappel, Flora Au
Can J Kidney Health Dis., 25 May 2020
Melissa Schoor (Capacity Building Committee member), Pavel S Roshanov, Matthew A Weir, Andrew A House
Can J Kidney Health Dis., 02 May 2020
Maryam Jafari, Kaval Kour, Shelley Giebel, Idunnu Omisore, Bhanu Prasad (Communications and Engagement Committee member)
N Engl J Med., 13 Feb 2020 Feb
Michael Walsh, Peter A Merkel, Chen-Au Peh, Wladimir M Szpirt, Xavier
Patient engagement is a relatively new way of conducting research in Canada and many researchers are probably still wondering how to do it well. Dr. Simon Hatcher and his team at the Ottawa Hospital developed a graphic novel style tip sheet, “Top 10 Recommendations for Researchers Working with Lived Experience Partners“.
The comic was created by people with lived experience of suicide at the REFLECT research forum which brought together patients and caregivers as well as suicide prevention researchers, trainees and policy-makers.
Dr. Bhanu Prasad and his research team are conducting a feasibility study of a randomized controlled trial investigating renal denervation as a possible treatment option in patients with Loin Pain Hematuria Syndrome (LPHS). Dr. Prasad presented this study at the CNTN meeting in November 2019 in Washington, D.C and we look forward to hearing more about the study at future CNTN meetings.
Loin Pain Hematuria Syndrome (LPHS) is a poorly understood clinical condition characterized by severe pain localized to the kidney but in the absence of identifiable urinary tract disease. Case reports/series have shown renal denervation via catheter-based radiofrequency ablation to be an effective therapeutic option for the treatment of LPHS. To determine whether catheter-based renal denervation is a meaningful addition to the treatment options in these often difficult to treat LPHS patients, a randomized clinical trial is needed. Prior to conducting a definitive trial that focuses on patient outcomes, ensuring the feasibility of undertaking such a trial is required. As such, we will conduct a single-centre randomized control feasibility trial designed to determine viability and provide framework and direction for a larger trial.
The research team will conduct a double-blinded, parallel-group, partial crossover, sham-controlled, randomized feasibility trial on 10 LPHS patients at the Regina General Hospital, Saskatchewan. Participants will be randomized into either renal denervation (treatment group) or a sham treatment (control group). Data (pain, quality of life, mood, disability) will be collected from both groups at baseline, 6 weeks, 3 and 6 months after the intervention. After the initial 6-month follow-up is over, the participants who received the sham procedure will cross over into the treatment group and will be followed for an additional 6 months in the same manner as the treatment group.
The lessons learnt from this trial will lay the framework and direction for conducting a multi-site randomized controlled trial involving a larger cohort of patients.
On behalf of the network, an abstract was submitted and accept for the CSN annual general meeting entitled, “A New Vision for Nephrology Trials in Canada” . The meeting was cancelled but the poster was submitted and can be found on the Can-SOLVE CKD website and the CSN poster website.
As part of the Can-SOLVE CKD virtual network update, a short 7-minute presentation was given by Alicia Murdoch, the CNTN coordinator. You can view the recording of the presentation here.
The Canadian Journal of Kidney Health and Disease has published the recommendations of the CSN Rapid Response Team regarding home dialysis. You can read the full article here.
The Canadian Society of Nephrology (CSN) announced their new president and board of directors today. We are pleased to share that 3 CNTN committee members are on the new board.
Rita Suri, member of the Scientific Operations and Executive committees, will be the chair of the CSN Scientific committee.
Amber Molnar, co-chair of the Communications and Engagement committee, will be representing the province of Ontario on the CSN board.
Bhanu Prasad, member of the Communications and Engagement committee, will be the chair of the CSN Community Nephrology committee.
Congratulations to everyone who was elected to the board.
Below is a list of COVID-19 specific study websites and websites with study lists. As the number of COVID-19 related studies increases, we will do our best to keep this page updated.
Active Canadian trials listed on ClinicalTrials.gov can be found here.
As the COVID-19 pandemic continues, most hospitals have halted all non-emergency visits, greatly affecting the conduct of clinical trials. Below are links to both Health Canada and the US Food and Drug Administration (FDA) guidance on the management of clinical trials during this time, as well as various Canadian research organizations. This post will be updated as more resources come to our attention.
We are working to collect a list of trial resources to help trialist overcome challenges and keep their research program moving forward. If you have had success or suggestions that you can share, please email amurdoch@cansolveckd.ca.
Canadian Institutes for Health Research FAQs on Impact of COVID-19 – https://cihr-irsc.gc.ca/e/51917.html#faq
Health Canada Guidance on Management of Clinical Trials during the COVID-19 pandemic – https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/management-clinical-trials-during-covid-19-pandemic.html
US FDA Guidance for Clinical Trials during COVID-19 – https://www.fda.gov/media/136238/download
COVID-19 Resources Canada – https://covid19resources.ca/activeresearch.html
Clinical Trials Ontario – https://www.ctontario.ca/covid-19-clinical-trial-resources/
Clinical Trials BC – https://www.clinicaltrialsbc.ca/updates-for-clinical-trials-bc-regarding-covid-19/
Canadian Institute of Health Information (CIHI) – https://www.cihi.ca/en/covid-19-resources
In response to the current situation and in light of the cancellation of the CSN Annual General Meeting, we will be cancelling the 2020 CNTN Spring Meeting in order to maintain the health and well-being our team, our members, and the community at large. If you have any questions, please contact Alicia Murdoch at amurdoch@cansolveckd.ca.
We thank you for your patience and continued support as we navigate this challenging, and unprecedented, situation.
